Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NORCROSS, Ga., March 09, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 11:30 a.m. Pacific Time. The conference is being held at the Ritz-Carlton in Dana Point, CA on March 12-15, 2017.
A live webcast of the presentation may be accessed on the conference’s website at http://wsw.com/webcast/roth31/galt. The webcast will be archived for 365 days following the live presentation on the Company’s website at www.galectintherapeutics.com.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contacts: Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]
